Lenoss Medical, Inc. recently secured a major technological breakthrough with the issuance of U.S. Patent No. 12740817. This patent, titled ‘Transversely displacing structures in the body’, introduces a powerful way to stabilize osteoporotic vertebral compression fractures. Surgeons can now repair damaged vertebrae using a full biological solution instead of traditional bone cement.
Advanced Stabilization for Vertebral Fractures
The innovation focuses on a biological allograft implant designed for treating vertebral compression fractures. This system uses a specialized device to transversely displace structures and deliver biological tissue directly into the vertebrae. A specialized mechanism creates a robust cortical structural matrix within the bone. This implant is fully osteoconductive and osteoinductive for long term biologic benefits. A precision design ensures the biological material integrates seamlessly with the surrounding anatomy while enabling continuous blood flow. This setup allows for an elegant and holistic healing process that avoids the risks of synthetic bone cement.
Rhode Island Patent of the Month Recognition
The invention, developed by inventor Dom Messerli, received the Rhode Island Patent of the Month award for October 2026, granted by Swanson Reed. Swanson Reed evaluates patents based on three core dimensions: technological radicalness, market scope, and economic utility. The technology demonstrates technological radicalness by pioneering a structural biological alternative to standard cement. The market scope is significant, addressing a large patient population suffering from osteoporosis and spinal fractures. Furthermore, the economic utility is substantial, as the natural healing approach aims to reduce postoperative complications and the need for subsequent fracture treatments.
R&D Tax Credit Eligibility in the USA
The practical applications of this patent provide a strong foundation for claiming the Research and Development (R&D) tax credit in the United States. To qualify, activities must involve resolving technical uncertainties through a process of experimentation grounded in the hard sciences. The engineering efforts to design a system capable of safely displacing structures within a vertebrae require rigorous biomechanical testing, material analysis, and prototyping. These iterative development phases directly align with the core requirements of the IRS four part test. Consequently, the labor, supplies, and clinical evaluation costs associated with bringing this biological allograft to market represent eligible expenditures that can significantly reduce the tax liabilities for the innovating company.
